{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:22:26Z","timestamp":1793409746044,"version":"4.5.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Interleukin 33 (IL-33) is a cytokine of the IL-1 family that acts as an alarmin in both innate and adaptive immunity. IL-33 is constitutively nuclear in epithelial and endothelial cells, where its activity is limited by nuclear retention. Release of IL-33 in response to cellular stress or injury can mediate type 2 immune responses or tissue repair, depending on the local tissue environment. IL-33 activity is regulated at multiple levels, including nuclear retention, oxidation, proteolytic processing, and metabolic regulation. Following its release, oxidation rapidly suppresses IL-33 activity, while mast cell and neutrophil proteases can generate smaller active fragments that target cells expressing the IL-33 ST2 receptor. Simultaneously, tissue metabolic status influences cellular responsiveness through the mTORC1 and AMPK pathways, which link metabolic capacity to effector function. These conditions may explain why IL-33 can mediate an inflammatory response, but in other circumstances, it contributes to tissue repair. Such pleiotropic properties may also underline the variability in clinical responses to IL-33\/ST2-targeted therapies across various diseases. The appreciation of IL-33 as a cytokine whose activity is conditioned by its structural, redox, and metabolic environment is critical to optimizing its therapeutic potential as a target.<\/jats:p>","DOI":"10.3389\/falgy.2026.1894127","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:20:43Z","timestamp":1784175643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Interleukin-33 at the intersection of inflammation and repair"],"prefix":"10.3389","volume":"7","author":[{"given":"Fernanda","family":"Martinez-Moreno","sequence":"first","affiliation":[{"name":"Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Jerschow","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor E.","family":"Ortega","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic","place":["Scottsdale, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kita","sequence":"additional","affiliation":[{"name":"Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic","place":["Scottsdale, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio E.","family":"Chiarella","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u201c\u2018Alarmin\u201d?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/embor.2008.145","article-title":"Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket","volume":"9","author":"Roussel","year":"2008","journal-title":"EMBO Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1038\/s41467-018-05485-x","article-title":"Chromatin regulates IL-33 release and extracellular cytokine activity","volume":"9","author":"Travers","year":"2018","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky Ari","year":"2015","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34255","DOI":"10.1038\/srep34255","article-title":"Extracellular IL-33 cytokine, but not endogenous nuclear IL-33, regulates protein expression in endothelial cells","volume":"6","author":"Gautier","year":"2016","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.4049\/jimmunol.1003020","article-title":"The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses","volume":"186","author":"Kouzaki","year":"2011","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1084\/jem.20112691","article-title":"Interleukin-1\u03b1 controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33","volume":"209","author":"Willart","year":"2012","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"AB104","DOI":"10.1016\/j.jaci.2009.12.410","article-title":"Stressed airway epithelial cells release a nuclear alarmin IL-33 and trigger Th2-type immune responses","volume":"125","author":"Kouzaki","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41590-021-01011-2","article-title":"Environmental allergens trigger type 2 inflammation through ripoptosome activation","volume":"22","author":"Brusilovsky","year":"2021","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/all.13158","article-title":"Oxidative stress serves as a key checkpoint for IL-33 release by airway epithelium","volume":"72","author":"Uchida","year":"2017","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41598-017-01863-5","article-title":"Intradermal administration of IL-33 induces allergic airway inflammation","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/art.24305","article-title":"Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis","volume":"60","author":"Palmer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/intimm\/dxq035","article-title":"Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis","volume":"22","author":"Matsuba-Kitamura","year":"2010","journal-title":"Int Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.4049\/jimmunol.0802387","article-title":"Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle Cells1","volume":"183","author":"Pr\u00e9fontaine","year":"2009","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation *","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2025.01.017","article-title":"Targeting alarmins in asthma: from bench to clinic","volume":"155","author":"Akenroye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e129429","DOI":"10.1172\/jci.insight.129429","article-title":"Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors","volume":"6","author":"Scott","year":"2021","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.immuni.2021.09.010","article-title":"IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation","volume":"54","author":"Faas","year":"2021","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7201","DOI":"10.1038\/s41467-023-43072-x","article-title":"The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration","volume":"14","author":"Cosway","year":"2023","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110672","DOI":"10.1016\/j.intimp.2023.110672","article-title":"Type 2 innate lymphoid cell-derived amphiregulin regulates type II alveolar epithelial cell transdifferentiation in a mouse model of bronchopulmonary dysplasia","volume":"122","author":"Yao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2016.06.040","article-title":"Perinatal licensing of thermogenesis by IL-33 and ST2","volume":"166","author":"Odegaard","year":"2016","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/ni.2131","article-title":"Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus","volume":"12","author":"Monticelli","year":"2011","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ni.3085","article-title":"The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells","volume":"16","author":"Vasanthakumar","year":"2015","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"eaax0416","DOI":"10.1126\/sciimmunol.aax0416","article-title":"Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33","volume":"4","author":"Mahlak\u00f5iv","year":"2019","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41590-018-0067-5","article-title":"Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33","volume":"19","author":"Cayrol","year":"2018","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/cvr\/cvy166","article-title":"Conflicting vascular and metabolic impact of the IL-33\/sST2 axis","volume":"114","author":"Altara","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1533335","DOI":"10.3389\/fimmu.2025.1533335","article-title":"IL-33\/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential","volume":"16","author":"Sheng","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefran\u00e7ais","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","author":"L\u00fcthi","year":"2009","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefran\u00e7ais","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"109915","DOI":"10.1016\/j.cbi.2022.109915","article-title":"IL-33 regulates M1\/M2 chemokine expression via mitochondrial redox-related mitophagy in human monocytes","volume":"359","author":"Lin","year":"2022","journal-title":"Chem-Biol Interact"},{"key":"B37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.bbrc.2012.04.005","article-title":"Nuclear IL-33 is a transcriptional regulator of NF-\u03baB p65 and induces endothelial cell activation","volume":"421","author":"Choi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","article-title":"Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation","volume":"55","author":"Bessa","year":"2014","journal-title":"J Autoimmun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.4049\/jimmunol.1003080","article-title":"The dual function cytokine IL-33 interacts with the transcription factor NF-\u03baB to dampen NF-\u03baB\u2013stimulated gene transcription","volume":"187","author":"Ali","year":"2011","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e106151","DOI":"10.15252\/embj.2020106151","article-title":"Nuclear IL-33\/SMAD signaling axis promotes cancer development in chronic inflammation","volume":"40","author":"Park","year":"2021","journal-title":"EMBO J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.xjidi.2023.100205","article-title":"Nuclear IL-33 plays an important role in EGFR-mediated keratinocyte migration by regulating the activation of signal transducer and activator of transcription 3 and NF-\u03baB","volume":"3","author":"Dai","year":"2023","journal-title":"JID Innov"},{"key":"B42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 axis in immune cells during inflammatory diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10762","DOI":"10.1073\/pnas.1509070112","article-title":"IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin\u2013EGFR interactions","volume":"112","author":"Monticelli","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.cell.2015.08.021","article-title":"A distinct function of regulatory T cells in tissue protection","volume":"162","author":"Arpaia","year":"2015","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1351405","DOI":"10.3389\/fimmu.2024.1351405","article-title":"The ST2+ Treg\/amphiregulin axis protects from immune-mediated hepatitis","volume":"15","author":"Wachtendorf","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","article-title":"Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection","volume":"42","author":"Kearley","year":"2015","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2011.12.020","article-title":"Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation","volume":"36","author":"Halim","year":"2012","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1172\/JCI65570","article-title":"Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease","volume":"123","author":"Byers","year":"2013","journal-title":"J Clin Invest"},{"key":"B49","first-page":"428","article-title":"Interleukin 33 is induced by tumor necrosis factor alpha and interferon gamma in keratinocytes and contributes to allergic contact dermatitis","volume":"23","author":"Taniguchi","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/jid.2012.185","article-title":"Regulation of IL-33 expression by IFN-\u03b3 and tumor necrosis factor-\u03b1 in normal human epidermal keratinocytes","volume":"132","author":"Meephansan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"19420","DOI":"10.1074\/jbc.M901744200","article-title":"Interleukin-33 is biologically active independently of caspase-1 cleavage *","volume":"284","author":"Talabot-Ayer","year":"2009","journal-title":"J Biol Chem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e166821","DOI":"10.1172\/jci.insight.166821","article-title":"Staphylococcus aureus exacerbates dermal IL-33\/ILC2 axis activation through evoking RIPK3\/MLKL-mediated necroptosis of dry skin","volume":"9","author":"Luo","year":"2024","journal-title":"JCI Insight"},{"key":"B53","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jaci.2023.10.031","article-title":"Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs","volume":"153","author":"Hayashi","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.jaci.2025.01.019","article-title":"Allergen-induced activation of epithelial P2Y2 receptors promotes adenosine triphosphate exocytosis and type 2 immunity in airways","volume":"155","author":"Srisomboon","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1002\/eji.201545501","article-title":"Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33","volume":"45","author":"Bandara","year":"2015","journal-title":"Eur J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","article-title":"Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation","volume":"164","author":"Oshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jaci.2014.09.044","article-title":"Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33","volume":"135","author":"Pfeffer","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"900826","DOI":"10.3389\/fimmu.2022.900826","article-title":"Interleukin-33: metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imm.13404","article-title":"IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8(+) T cells","volume":"165","author":"Liang","year":"2022","journal-title":"Immunology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature14115","article-title":"Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity","volume":"519","author":"Brestoff","year":"2015","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12967-024-05180-0","article-title":"IL-33 regulates adipogenesis via Wnt\/\u03b2-catenin\/PPAR-\u03b3 signaling pathway in preadipocytes","volume":"22","author":"Xu","year":"2024","journal-title":"J Transl Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1189\/jlb.1207830","article-title":"Induction of IL-33 expression and activity in central nervous system glia","volume":"84","author":"Hudson","year":"2008","journal-title":"J Leukocyte Biol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e131347","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/jdv.20388","article-title":"Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: a phase 2a randomized controlled trial (FRONTIER-2)","volume":"39","author":"Silverberg","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"00183-2025","DOI":"10.1183\/23120541.00183-2025","article-title":"FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma","volume":"12","author":"Corren","year":"2026","journal-title":"ERJ Open Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2402231","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"key":"B75","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1038\/s41467-023-40993-5","article-title":"A tissue-intrinsic IL-33\/EGF circuit promotes epithelial regeneration after intestinal injury","volume":"14","author":"Calafiore","year":"2023","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41586-025-09331-1","article-title":"Epithelial cell membrane perforation induces allergic airway inflammation","volume":"645","author":"Shi","year":"2025","journal-title":"Nature"},{"key":"B77","first-page":"198","article-title":"IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial","volume":"1","author":"Crim","year":"2022","journal-title":"J. Allergy Clin Immunol: Glob"},{"key":"B78","doi-asserted-by":"crossref","first-page":"e0281205","DOI":"10.1371\/journal.pone.0281205","article-title":"Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial","volume":"18","author":"Akinseye","year":"2023","journal-title":"PLOS ONE"},{"key":"B79","doi-asserted-by":"crossref","first-page":"00718","DOI":"10.1183\/23120541.00718-2023","article-title":"AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD","volume":"10","author":"Rabe","year":"2024","journal-title":"ERJ Open Research"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1894127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:20:45Z","timestamp":1784175645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2026.1894127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":79,"alternative-id":["10.3389\/falgy.2026.1894127"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2026.1894127","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1894127"}}